Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“Hanx Bio”) disclosed a Next Day Disclosure Return showing that on 5 June 2026 it repurchased 39,100 H shares on the Hong Kong Stock Exchange.

The on-market buy-back was executed within a price range of HKD 26.52 to HKD 27.98 per share, with a volume-weighted average cost of HKD 27.23. Total consideration amounted to HKD 1.06 million.

Following the transaction: • Issued shares (excluding treasury shares) fell from 135.21 million to 135.17 million, a decrease of 0.03%. • Treasury shares rose from 1.01 million to 1.04 million. • Total issued share capital remained unchanged at 136.22 million, as the repurchased shares are being held in treasury rather than cancelled.

Under the repurchase mandate granted on 12 February 2026, Hanx Bio is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 1.04 million shares, representing 0.77% of the company’s issued shares on the mandate date and roughly 7.66% of the authorised limit.

In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 5 July 2026. The board confirmed that all buy-backs were conducted within regulatory guidelines.